Vol. 20 No. 1 (2021)
Original Articles

Comparative evaluation of the Phoenix®, VITEK® 2, E-test® and microdilution test for vancomycin susceptibility testing in Staphylococcus aureus isolated from bloodstream infection

PDF
  • Daiana C. S. Rodrigues,
  • Ana Paula P. Costa,
  • Paulo Roberto V. Santos,
  • Elizabeth A. Marques,
  • José F. Nogueira Neto,
  • Robson S. Leão
Daiana C. S. Rodrigues
Departamento de Microbiologia, Imunologia e Parasitologia, Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro. Rio de Janeiro, RJ, Brazil.
Bio
Ana Paula P. Costa
Instituto de Biologia Roberto Alcântara Gomes
Bio
Paulo Roberto V. Santos
Hospital Universitário Pedro Ernesto
Bio
Elizabeth A. Marques
Universidade do Estado do Rio de Janeiro
Bio
José F. Nogueira Neto
Universidade do Estado do Rio de Janeiro
Bio
Robson S. Leão
Universidade do Estado do Rio de Janeiro
Bio
DOI: https://doi.org/10.12957/bjhbs.2021.59740

Published 2021-07-03

Keywords

  • Staphylococcus aureus,
  • Vancomycin,
  • Bloodstream infection

How to Cite

1.
Daiana C. S. Rodrigues, Ana Paula P. Costa, Paulo Roberto V. Santos, Elizabeth A. Marques, José F. Nogueira Neto, Robson S. Leão. Comparative evaluation of the Phoenix®, VITEK® 2, E-test® and microdilution test for vancomycin susceptibility testing in Staphylococcus aureus isolated from bloodstream infection. BJHBS [Internet]. 2021 Jul. 3 [cited 2024 Oct. 11];20(1):11-8. Available from: https://bjhbs.hupe.uerj.br/bjhbs/article/view/46

Copyright (c) 2021 Brazilian Journal of Health and Biomedical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC

Abstract

Introduction: Staphylococcus aureus bacteremia causes significant morbidity and mortality, mainly by methicillin-resistant S. aureus (MRSA). Currently, vancomycin is the main choice for the treatment of infections by MRSA. Broth microdilution (BMD) remains the gold standard for measuring vancomycin MIC. 

PDF

Metrics

Metrics Loading ...

References

  1. Guimaraes AO, Cao Y, Hong K, et al. A prognostic model of persistent bacteremia and mortality in complicated S. aureus bloodstream infection. Clin Infect Dis. 2018;68(9):1502-1511.
  2. Adani S, Bhowmick T, Weinstein MP, et al. Impact of Vancomycin MIC on Clinical Outcomes of Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with Vancomycin at an Institution with Suppressed MIC Reporting. Antimicrob Agents Chemother. 2018;62(4):e02512-17.
  3. Balakuntla J, Prabhakara S, Arakere G. Novel rearrangements in the staphylococcal cassette chromosome mec type V elements of Indian ST772 and ST672 methicillin resistant Staphylococcus aureus strains. PLoS One. 2014;9(4):e94293.
  4. Kaya H, Hasman H, Larsen J, et al. SCCmecFinder, a Web-Based Tool for Typing of Staphylococcal Cassette Chromosome mec in Staphylococcus aureus Using WholeGenome Sequence Data. mSphere. 2018;3(1)e00612-17.
  5. Kalimuddin S, Chan YFZ, Phillips R, et al. A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations – results of a prematurely terminated study. Trials. 2018;19(1):305.
  6. Zuma AVP, Lima DF, Assef APDAC, et al. Molecular characterization of methicillin-resistant Staphylococcus aureus isolated from blood in Rio de Janeiro displaying susceptibility profiles to non-β-lactam antibiotics. Brazilian J Microbiol. 2017;48(2):237-241.
  7. Diaz R, Ramalheira E, Afreixo V, et al. Evaluation of vancomycin MIC creep in Staphylococcus aureus. J Glob Antimicrob Resist. 2017;10:281–4.
  8. Edwards B, Milne K, Lawes T, et al. Vancomycin MIC “Creep”Method Dependent? Analysis of Methicillin-Resistant Staphylococcus aureus Susceptibility Trends in Blood Isolates from North East Scotland from 2006 to 2010. J Clin Microbiol. 2012;50(2):318–25.
  9. van Hal SJ, Lodise TP, Paterson DL. The Clinical Significance of Vancomycin Minimum Inhibitory Concentration in Staphylococcus aureus Infections: A Systematic Review and Meta-analysis. Clin Infect Dis. 2012;54(6):755–71.
  10. San-Juan R, Fernández-Ruiz M, Gasch O, et al. High vancomycin MICs predict the development of infective endocarditis in patients with catheter-related bacteraemia due to methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 2017;72(7):2102–9.
  11. de Sanctis JT, Swami A, Sawarynski K, et al. Is there a clinical association of vancomycin MIC creep, agr group II locus, and treatment failure in MRSA bacteremia? Diagn Mol Pathol. 2011;20(3):184–8.
  12. Park S-Y, Oh I-H, Lee H-J, al. Impact of Reduced Vancomycin MIC on Clinical Outcomes of Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrob Agents Chemother. 2013;57(11):5536–42.
  13. Hos NJ, Jazmati N, Stefanik D, et al. Determining vancomycin Etest MICs in patients with MRSA bloodstream infection does not support switching antimicrobials. J Infect. 2017;74(3):248–59.
  14. CLSI (2019) Performance Standards for Antimicrobial Susceptibility Testing; Twenty-seventh informational supplement. CLSI, M100-S28. Wayne, PA: Clinical and Laboratory Standards Institute.
  15. Rossatto FCP, Proenca LA, Becker AP, et al. Evaluation of methods in detecting vancomycin MIC among MRSA isolates and the changes in accuracy related to different MIC values.Rev Inst Med Trop Sao Paulo. 2014;56(6):469–72.
  16. Agrawal DC. Methicillin Resistant Staphylococcus aureus: Inconsistencies in Vancomycin Susceptibility Testing Methods, Limitations and Advantages of each Method. J Clin DIAGNOSTIC Res. 2015; 9(10):DC01-4.
  17. Phillips C, Wells N, Martinello M, et al. Optimizing the detection of methicillin-resistant Staphylococcus aureus with elevated vancomycin minimum inhibitory concentrations within the susceptible range. Infect Drug Resist. 2016;9:87-92.
  18. Bhatt M, Burgess DR, Wallace KL, et al. Impact of Susceptibility Testing Method on Antibiotic Selection for Methicillin-Resistant taphylococcus aureus (MRSA) Bacteremia. Open Forum Infect Dis. 2018;5(1):511–2.
  19. Han JH, Edelstein PH, Lautenbach E. Reduced vancomycin susceptibility and staphylococcal cassette chromosome mec (SCCmec) type distribution in methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother. 2012;67(10):2346–9.
  20. Menzies RE. Comparison of coagulase, deoxyribonuclease (DNase), and heat-stable nuclease tests for identification of Staphylococcus aureus. J Clin Pathol. 1977;30(7):606–8.
  21. Boye K, Bartels MD, Andersen IS, et al. A new multiplex PCR for easy screening of methicillin-resistant Staphylococcus aureus SCC mec types I-V. Clin Microbiol Infect. 2007;13(7):725-7.
  22. Álvarez R, López Cortés LE, Molina J, et al. Optimizing the Clinical Use of Vancomycin. Antimicrob Agents Chemother. 2016;60(5):2601–9.
  23. Toyokawa M, Francisco M, Nishi I, et al. Accuracy of Commercial Susceptibility Testing Method for Measuring Vancomycin MIC Against Methicillin-Resistant Staphylococcus aureus (MRSA). Lab Med. 2011; 42(8)473–477.
  24. Holmes NE, Johnson PDR, Howden BP. Relationship between Vancomycin-Resistant Staphylococcus aureus, VancomycinIntermediate S. aureus, High Vancomycin MIC, and Outcome in Serious S. aureus Infections. J Clin Microbiol. 2012;50(8):2548–52.
  25. Rybak MJ, Vidaillac C, Sader HS, et al. Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: Comparison of Etest and three automated testing methods. J Clin Microbiol. 2013;51(7):2077–81.
  26. Kruzel MC, Lewis CT, Welsh KJ, et al. Determination of Vancomycin and Daptomycin MICs by Different Testing Methods for Methicillin-Resistant Staphylococcus aureus. JClin Microbiol. 2011;49(6):2272–3.
  27. Marx A, Daniels L, Miller MB, et al. Vancomycin minimum inhibitory concentration is not a substitute for clinical judgment: Response to healthcare-associated ventriculitis and meningitis. Clin. Infect. Dis. 2017; 65(8):1428–1429.
  28. Swenson JM, Anderson KF, Lonsway DR, et al. Accuracy of 18 bjhbs.hupe.uerj.br Original article Commercial and Reference Susceptibility Testing Methods for Detecting Vancomycin-Intermediate Staphylococcus aureus. JClin Microbiol. 2009;47(7):2013–7.
  29. Liu C, Bayer A, Cosgrove SE, Daum RS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clin Infect Dis. 2011;52(3):e18–55.
  30. van Hal SJ, Paterson DL. Systematic Review and MetaAnalysis of the Significance of Heterogeneous VancomycinIntermediate Staphylococcus aureus Isolates. Antimicrob Agents Chemother. 2011;55(1):405–10.
  31. Tomczak H, Szałek E, Błażejewska W, et al. The need to assay the real MIC when making the decision to eradicate Staphylococcus aureus with vancomycin. PostepyHig Med Dosw. 2013;67:921–5.
  32. Sousa AGP, Da Costa TM, Cavalcante FS, et al. Vancomycin minimum inhibitory concentrations using different susceptibility methods in Staphylococcus aureus isolates. J Infect Dev Ctries. 2014;8(04):558–60.
  33. Manfredini C, Picoli SU, Becker AP. Comparação de métodos na determinação de sensibilidade à vancomicina em Staphylococcus aureus resistente à meticilina. J Bras Patol e Med Lab. 2011;47(2):141–145.
  34. Goldman JL, Harrison CJ, Myers AL, et al. No Evidence of Vancomycin Minimal Inhibitory Concentration Creep or Heteroresistance Identified in Pediatric Staphylococcus aureus Blood Isolates. Pediatr Infect Dis J. 2014;33(2):216–8.
  35. Ma X, Gao P, Lv X, et al. Vancomycin MIC creep in methicillinresistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China. Indian J Med Microbiol. 2015;33(2):262.
  36. Wilcox M, Al-Obeid S, Gales A, et al. Reporting elevated vancomycin minimum inhibitory concentration in methicillin resistant Staphylococcus aureus: consensus by an International Working Group. Future Microbiol. 2019;14(4):345–52.
  37. Hsu DI, Hidayat LK, Quist R, et al. Comparison of methodspecific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillinresistant Staphylococcus aureus (MRSA) infections. Int JAntimicrob Agents. 2008;32(5):378–85.
  38. Sader HS, Rhomberg PR, Jones RN. Nine-Hospital Study Comparing Broth Microdilution and Etest Method Results for Vancomycin and Daptomycin against Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53(7):3162–5.
  39. da Costa TM, Morgado PGM, Cavalcante FS, et al. Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital. PLoS One. 2016;11(8):e0160506.
  40. Yusof A, Engelhardt A, Karlsson A, et al. Evaluation of a New Etest Vancomycin-Teicoplanin Strip for Detection of Glycopeptide-Intermediate Staphylococcus aureus (GISA), in Particular, Heterogeneous GISA. J Clin Microbiol. 2008;46(9):3042–7.